Predicting environmental chemical factors associated with disease-related gene expression data

<p>Abstract</p> <p>Background</p> <p>Many common diseases arise from an interaction between environmental and genetic factors. Our knowledge regarding environment and gene interactions is growing, but frameworks to build an association between gene-environment interactions and disease using preexisting, publicly available data has been lacking. Integrating freely-available environment-gene interaction and disease phenotype data would allow hypothesis generation for potential environmental associations to disease.</p> <p>Methods</p> <p>We integrated publicly available disease-specific gene expression microarray data and curated chemical-gene interaction data to systematically predict environmental chemicals associated with disease. We derived chemical-gene signatures for 1,338 chemical/environmental chemicals from the Comparative Toxicogenomics Database (CTD). We associated these chemical-gene signatures with differentially expressed genes from datasets found in the Gene Expression Omnibus (GEO) through an enrichment test.</p> <p>Results</p> <p>We were able to verify our analytic method by accurately identifying chemicals applied to samples and cell lines. Furthermore, we were able to predict known and novel environmental associations with prostate, lung, and breast cancers, such as estradiol and bisphenol A.</p> <p>Conclusions</p> <p>We have developed a scalable and statistical method to identify possible environmental associations with disease using publicly available data and have validated some of the associations in the literature.</p

Pharmaceutical Compositions Containing Procyanidins From Rhizophora Mangle Bark Fractions

A presente invenção descreve duas composições medicamentosas derivadas de duas frações de Rizophora mangle, isoladamente. Adicionalmente também são descritas novas frações moleculares com potencial para tratamento de doenças inflamatórias gastrointestinais (DM) bem como as possíveis interações imunológicas sistémicas envolvidas em sua administração. As composições medicamentosas são indicadas principalmente para tratamento de reto-colite ulcerativa inespecífica e Doença de Grohn, ambas caracterizadas por processo inflamatório crônico e descontrolado ao intestino mediado por células do sistema imune. Dessa forma, as composições medicamentosas descritas nesta invenção permitem melhora na lesão da mucosa do cólon, dos conteúdos antioxidantes (GSH) e de enzimas (GSH-Px, catalase), bem como na modulação de marcadores inflamatórios (MPO, TBARS, COX-1 e COX-2) e citocinas (TNF-a, IL-6,IL-12 e IL,-12).WO2014131095 (A1)C07D311/04A61K31/35A61K36/185A61P1/04C07D311/40WO2013BR00536C07D311/04A61K31/35A61K36/185A61P1/04C07D311/40WO9737673 (A1)WO2011126537 (A2)US2012040033 (A1

Pharmaceutical Compositions Containing A Fraction Obtained From Rhizophora Mangle Extract And Use Thereof

A presente invenção descreve urna forma de fracionamento de extrato de R. mangle através da qual é possível concentra-se de forma eficientemente quantidade significativa de taninos complexos. A fração obtida pelo método proposto apresenta efeito surpreendente no tratamento de úlceras e injúrias gastrointestinais, quando comparadas com o medicamento que é atualmente utilizado para essa finalidade, por utilizar dose até 60 vezes menor do que esse e com a mesma eficiência. Dessa forma, são descritas na presente invenção composições medicamentosas ou farmacêuticas envolvendo a fração butanólica obtida, bem como a proposição dos compostos contido nessa fração.The present invention describes a method for fractionating an R. mangle extract, by means of which it is possible to efficiently concentrate a significant quantity of complex tannins. The fraction obtained by means of the proposed method has a surprising effect in the treatment of ulcers and gastrointestinal injuries, compared to the drug that is currently used for this purpose, since a dose up to 60 times lower than that of the currently used drug can be used and is as effective. Therefore, pharmaceutical or medicinal compositions involving the butanol fraction obtained are described in the present invention, as well as the proposal of the compounds contained in said fraction.WO2014071480 (A1)C07D311/04A61K31/35A61K36/185A61P1/04C07D311/40WO2013BR00458C07D311/04A61K31/35A61K36/185A61P1/04C07D311/40WO9737673 (A1)WO2011126537 (A2)US2012040033 (A1